NO20076382L - Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer - Google Patents

Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer

Info

Publication number
NO20076382L
NO20076382L NO20076382A NO20076382A NO20076382L NO 20076382 L NO20076382 L NO 20076382L NO 20076382 A NO20076382 A NO 20076382A NO 20076382 A NO20076382 A NO 20076382A NO 20076382 L NO20076382 L NO 20076382L
Authority
NO
Norway
Prior art keywords
treatment
docosahexa
glycerides
oil
tumorigenic diseases
Prior art date
Application number
NO20076382A
Other languages
English (en)
Other versions
NO336953B1 (no
Inventor
Pedrol Joan Carles Domingo
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Publication of NO20076382L publication Critical patent/NO20076382L/no
Publication of NO336953B1 publication Critical patent/NO336953B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen angår anvendelsen av en olje beriket med DHA triglyserider for fremstilling av en farmasøytisk sammensetning for behandlingen av en tumorøs sykdom, nevnte olje er beriket i en konsentrasjon på opptil 70 vekt% i forhold til den totale vekten av nevnte farmasøytiske sammensetning, og er i en prosentandel på minst 50% i forhold til alle acylgrupper av fettsyrer i nevnte olje.
NO20076382A 2005-05-12 2007-12-11 Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer NO336953B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501141A ES2264886B1 (es) 2005-05-12 2005-05-12 Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
PCT/EP2006/061833 WO2006120120A1 (en) 2005-05-12 2006-04-26 Use of docosahexaenoic glycerides for the treatment of tumorous diseases

Publications (2)

Publication Number Publication Date
NO20076382L true NO20076382L (no) 2008-02-08
NO336953B1 NO336953B1 (no) 2015-11-30

Family

ID=36809521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076382A NO336953B1 (no) 2005-05-12 2007-12-11 Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer

Country Status (13)

Country Link
US (3) US20080207947A1 (no)
EP (1) EP1881824B1 (no)
JP (2) JP5893235B2 (no)
CA (1) CA2614192C (no)
DK (1) DK1881824T3 (no)
ES (2) ES2264886B1 (no)
HK (1) HK1113319A1 (no)
IL (1) IL187274A (no)
NO (1) NO336953B1 (no)
NZ (1) NZ563301A (no)
PL (1) PL1881824T3 (no)
PT (1) PT1881824E (no)
WO (1) WO2006120120A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
KR20130101596A (ko) * 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
NZ569676A (en) * 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN101903028B (zh) * 2007-12-19 2013-06-05 普罗米蒂克生物科学公司 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
EP2599485B1 (en) * 2010-07-26 2019-02-20 FUJIFILM Corporation Fat-containing composition and oral formulation containing same
CA2909409A1 (en) 2013-04-22 2014-10-30 Smartfish As Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer
KR101665253B1 (ko) 2015-06-19 2016-10-25 순천향대학교 산학협력단 도코사헥사에노산 및 트리아신 씨를 포함하는 것을 특징으로 하는 자궁내막암 치료 및 예방용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JP2572692B2 (ja) * 1991-07-24 1997-01-16 ボーソー油脂 株式会社 ドコサヘキサエン酸トリグリセリドの製造法
JPH05139968A (ja) * 1991-11-14 1993-06-08 Sagami Chem Res Center メダラシン活性促進剤
JPH0616548A (ja) * 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
JPH06116585A (ja) * 1992-10-09 1994-04-26 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
JP3526632B2 (ja) * 1994-08-22 2004-05-17 旭化成ケミカルズ株式会社 高度不飽和脂肪酸含有油脂
JPH1057086A (ja) * 1996-08-20 1998-03-03 Asahi Chem Ind Co Ltd 高濃度ドコサヘキサエン酸モノグリセリドの製造方法
WO2001017524A1 (en) * 1999-09-09 2001-03-15 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
JP2002180082A (ja) * 2000-12-11 2002-06-26 Maruha Corp 摂取物
US20040052837A1 (en) * 2002-06-27 2004-03-18 William Stillwell Lipid conjugated anti-cancer drugs and methods of use thereof
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
EP1881824B1 (en) 2014-12-24
ES2264886B1 (es) 2008-02-01
CA2614192C (en) 2014-03-18
PL1881824T3 (pl) 2015-06-30
ES2531599T3 (es) 2015-03-17
EP1881824A1 (en) 2008-01-30
NZ563301A (en) 2010-08-27
JP2008540484A (ja) 2008-11-20
IL187274A (en) 2011-11-30
IL187274A0 (en) 2008-06-05
WO2006120120A1 (en) 2006-11-16
DK1881824T3 (en) 2015-02-23
ES2264886A1 (es) 2007-01-16
CA2614192A1 (en) 2006-11-16
HK1113319A1 (en) 2008-10-03
US9271954B2 (en) 2016-03-01
JP5893235B2 (ja) 2016-03-23
US20170333381A9 (en) 2017-11-23
NO336953B1 (no) 2015-11-30
US20090318553A1 (en) 2009-12-24
PT1881824E (pt) 2015-03-26
US20080207947A1 (en) 2008-08-28
JP6038841B2 (ja) 2016-12-07
JP2014208677A (ja) 2014-11-06
US20160193175A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
Wu et al. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
EA200970360A1 (ru) Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
JP2006219454A5 (no)
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR062305A1 (es) Metodos para mejorar la salud osea y la salud muscular
JP2008540484A5 (no)
CO6341563A2 (es) Compuestos organicos
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
EA200970238A1 (ru) ПРИМЕНЕНИЕ МАСЕЛ С DPA(n-6) В ДЕТСКОМ ПИТАНИИ
DE602005010876D1 (de) Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
RU2008108078A (ru) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
NO20074318L (no) Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
BR112014005546A2 (pt) ácidos graxos ômega para tratamento de doenças
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
DE60134931D1 (de) Phosphatidyl-L-serin und Phosphatidylsäure zur Behandlung von Depression und Stresszuständen
ATE516366T1 (de) Regulierte aptamer-therapeutika
GB2544204A (en) Preparation and composition of medium chain triglycerides containing substantial amount of lauric acid
AR055939A1 (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees